Skip to main content
TipRanks
Go Ultimate75% OFF

Diaceutics (DIUXF) Stock Price & Analysis

3 Followers

DIUXF Stock Chart & Stats

$2.61$0.04(1.56%)
At close: 4:00 PM EST
$1$1.5$2Aug 8Jan 15May 28Sep 23
Day’s Range
$2.47 - $2.74
52-Week Range
$1.37 - $2.74
Previous Close
$2.57
Volume
N/A
Average Volume (3M)
0
Market Cap
$220.90M
Enterprise Value
$117.62M
Total Cash (Recent Filing)
$8.10M
Total Debt (Recent Filing)
$2.09M
Price to Earnings (P/E)
―
Beta
0.11
Next Earnings
Mar 15, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet

Very low leverage gives Diaceutics financial flexibility to invest in its diagnostics intelligence platform and services without substantial debt pressure. A modest debt burden also improves resilience if growth slows, while sizable equity provides capacity to fund operations and strategic expansion.

Revenue Growth And Scale

Sustained revenue scaling indicates increasing demand for Diaceutics' diagnostics intelligence and precision-medicine services. Growth from a larger base can support operating leverage, strengthen customer relevance across pharma and biotech, and create a broader foundation for future recurring platform revenue.

Return To Positive Free Cash Flow

Positive operating and free cash flow represent a meaningful improvement in the company's ability to fund itself internally. If maintained, better cash generation can reduce dependence on external capital, support platform investment, and provide greater flexibility as precision-medicine demand develops.

Bears Say

Operating Profitability Remains Unproven

Despite revenue growth and a small net profit, continued operating losses show that the core business has not yet established durable operating profitability. Margin volatility may limit reinvestment capacity and makes it harder to assess whether future growth will translate consistently into stronger earnings.

Very Low Return On Equity

Minimal returns on the equity base indicate that Diaceutics has not consistently converted invested capital into meaningful earnings. This weak capital productivity can constrain long-term compounding and suggests that improvements in revenue and net income have not yet produced a durable economic return.

Uneven Historical Cash Conversion

The 2025 cash-flow rebound is encouraging, but prior large outflows and low operating cash generation point to inconsistent cash conversion and spending discipline. Such variability can make internal funding less dependable and may complicate investment planning through the next several quarters.

Diaceutics News

DIUXF FAQ

What was Diaceutics’s price range in the past 12 months?
Diaceutics lowest stock price was $1.37 and its highest was $2.74 in the past 12 months.
What is Diaceutics’s market cap?
Diaceutics’s market cap is $220.90M.
When is Diaceutics’s upcoming earnings report date?
Diaceutics’s next earnings report is estimated for Mar 15, 2027 (not yet confirmed), which is in 118 days.
How were Diaceutics’s earnings last quarter?
Diaceutics released its earnings results on Sep 22, 2026. The company reported -$0.044 earnings per share for the quarter, missing the consensus estimate of -$0.037 by -$0.007.
Is Diaceutics overvalued?
According to Wall Street analysts Diaceutics’s price is currently Undervalued.
Does Diaceutics pay dividends?
Diaceutics does not currently pay dividends.
What is Diaceutics’s EPS estimate?
Diaceutics’s EPS estimate is 0.06.
How many shares outstanding does Diaceutics have?
Diaceutics has 85,291,960 shares outstanding.
What happened to Diaceutics’s price movement after its last earnings report?
Diaceutics reported an EPS of -$0.044 in its last earnings report, missing expectations of -$0.037. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Diaceutics?
Currently, no hedge funds are holding shares in DIUXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology